Аңдатпа
Rational selection of medicines with an assessment of their pharmacoeconomic effectiveness is the most effective way to ensure safe and efficient treatment and economical use of budget funds allocated for drug therapy, as well as to reduce the time of hospitalization and treatment of patients. The purpose of the research was to evaluate the pharmacoeconomic effectiveness of using the subcutaneous and intravenous forms of drug Trastuzumab. Research tasks: 1. Estimate costs when using subcutaneous trastuzumab in an outpatient chemotherapy room (OCR). 2. Estimate costs when using intravenous trastuzumab in a day patient department (DPD) 3. Estimate costs when using intravenous trastuzumab in a round-the-clock hospital Results: The paper presents the pharmacoeconomic analysis of targeted therapy with trastuzumab in two forms for intravenous (IV) administration and trastuzumab emtansine for subcutaneous (SC) administration in breast cancer by cost minimization method. The costs include the cost of used drugs according to the price-list of the unified national distributor SK Pharmacia as of January 1, 2018. At comparable efficacy and toxicity, the estimated cost-effectiveness of trastuzumab per 100 patients per year is KZT16,939,600 ($50,972) for SC administration in OCR and IV administration in DPD vs. KZT41,783,200 ($125,728) for SC administration in OCR and IV administration in a round-theclock hospital.